The importance of endothelin-1 for vascular dysfunction in cardiovascular disease

被引:378
作者
Boehm, Felix [1 ]
Pernow, John [1 ]
机构
[1] Karolinska Inst, Karolinska Univ Hosp, Dept Cardiol, S-17176 Stockholm, Sweden
关键词
atherosclerosis; coronary disease; endothelins; endothelial function; endothelial receptors;
D O I
10.1016/j.cardiores.2007.06.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Endothelin (ET)-1 is a potent vasoconstrictor peptide originally isolated from endothelial cells. Its production is stimulated in a variety of different cell types under the influence of risk factors for cardiovascular disease and during the development of cardiovascular disease. Based on these observations and the biological effects induced by ET-1, including profound vasoconstriction, pro-inflammatory actions, mitogenic and proliferative effects, stimulation of free radical formation and platelet activation, ET-1 has been implicated as an important factor in the development of vascular dysfunction and cardiovascular disease. In the following the pathogenic role of ET-1, the mechanisms underlying the involvement of ET-1 for the development of vascular dysfunction and the potentially beneficial therapeutic effects of selective ETA and dual ETA/ETB receptor antagonists will be discussed. In particular the changes of pathophysiological importance mediated by ET-1 in clinical studies are reviewed. These changes may be of significance for the development of various cardiovascular diseases beyond pulmonary arterial hypertension which is the currently approved indication for ET receptor antagonists. (C) 2007 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:8 / 18
页数:11
相关论文
共 99 条
[51]   Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries [J].
Kinlay, S ;
Behrendt, D ;
Wainstein, M ;
Beltrame, J ;
Fang, JC ;
Creager, MA ;
Selwyn, AP ;
Ganz, P .
CIRCULATION, 2001, 104 (10) :1114-1118
[52]   Novel 31-amino-acid-length endothelins cause constriction of vascular smooth muscle [J].
Kishi, F ;
Minami, K ;
Okishima, N ;
Murakami, M ;
Mori, S ;
Yano, M ;
Niwa, Y ;
Nakaya, Y ;
Kido, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 248 (02) :387-390
[53]   Endothelin blockade potentiates endothelial protective effects of ACE inhibitors in saphenous veins [J].
Ko, L ;
Maitland, A ;
Fedak, PWM ;
Dumont, AS ;
Badiwala, M ;
Lovren, F ;
Triggle, CR ;
Anderson, TJ ;
Rao, V ;
Verma, S .
ANNALS OF THORACIC SURGERY, 2002, 73 (04) :1185-1188
[54]  
KOWALA MC, 1995, AM J PATHOL, V146, P819
[55]   The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion [J].
Lefer, AM ;
Lefer, DJ .
CARDIOVASCULAR RESEARCH, 1996, 32 (04) :743-751
[56]   CIRCULATING AND TISSUE ENDOTHELIN IMMUNOREACTIVITY IN HYPERCHOLESTEROLEMIC PIGS [J].
LERMAN, A ;
WEBSTER, MWI ;
CHESEBRO, JH ;
EDWARDS, WD ;
WEI, CM ;
FUSTER, V ;
BURNETT, JC .
CIRCULATION, 1993, 88 (06) :2923-2928
[57]   Endothelial function - Cardiac events [J].
Lerman, A ;
Zeiher, AM .
CIRCULATION, 2005, 111 (03) :363-368
[58]   The effect of cerivastatin therapy on vascular responses to endothelia antagonists in humans [J].
Leslie, SJ ;
Spratt, JC ;
Grieg, L ;
Attina, T ;
Denvir, MA ;
Webb, DJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 :S410-S412
[59]   NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension [J].
Li, L ;
Watts, SW ;
Banes, AK ;
Galligan, JJ ;
Fink, GD ;
Chen, AF .
HYPERTENSION, 2003, 42 (03) :316-321
[60]  
Libby P, 2002, NATURE, V420, P868, DOI [10.1038/nature01323, 10.1161/ATVBAHA.108.179705]